Today, we will be studying why Scynexis (SCYX) is an attractive investment for 2020.
Company overview
Scynexis is a clinical-stage biopharmaceutical company focused on the development of innovative anti-infective therapies. The company's lead asset, Ibrexafungerp, is currently being evaluated for a range of fungal infections including VVC (vulvovaginal candidiasis), invasive candidiasis, invasive aspergillosis, and refractory invasive fungal infections.
Why antifungals are emerging as a major growth opportunity?
Today, Fungal infections are emerging as a public threat. The rising rate of invasive fungal infections in the hospital setting has dramatically increased mortality